There have been changes in the collection of proprietary Chinese medicines!

　　On August 30, the Hunan Provincial Medical Insurance Bureau issued the "Notice on Doing a Good Job in the Implementation of Centralized Procurement of Chinese Patent Medicines in Inter-Provincial Alliances" (hereinafter referred to as the "Notice"), announcing that the alliance will be launched on October 20.
the selected result
.
The "Notice" clarifies that medical institutions must unblock the channels for selected drugs to enter the hospital, conduct purchase transactions through the medical insurance recruitment system, and must not purchase drugs outside the Internet or through non-regulated channels
.
The purchase amount of all drugs in the centralized procurement catalog of Chinese patent medicines (including selected drugs and non-selected drugs listed on the Internet) shall not exceed 85% of the same period of the previous year
.
According to the "Notice", in principle, the procurement period for the centralized procurement of Chinese patent medicines is 2 years, which will be calculated from the date of implementation of the selected results
.
The results of the centralized procurement of the Chinese Patent Medicine Alliance will be implemented on October 20, 2022 on the province's unified medical insurance information platform "Drugs and Medical Consumables Recruitment and Procurement Management Subsystem"
.
At the same time, all drugs of the same product group will stop being purchased on the original provincial centralized pharmaceutical procurement platform
.
The selected varieties announced this time are detailed in the table at the end of the article
.
In order to encourage fair competition, the "Notice" clarifies that if the average daily treatment cost of non-selected drugs in the same product group is lower than the minimum average daily treatment cost of selected drugs in the same product group, they can be included in the selected list upon application
.
For non-selected drugs, the highest price limit for the entire group is set based on the highest value of the price of the selected drug with the largest drop in the same product group and the current highest online price in Hunan Province, and the price limit is implemented
.
In terms of payment settlement, direct payment for goods will be implemented on a trial basis, and the payment for selected drugs will be directly settled by the medical insurance fund
.
Before the trial of direct settlement of medical insurance funds, the payment for medicines will be temporarily settled offline by medical institutions and relevant pharmaceutical enterprises .
In principle, the payment for the selected products should not be settled more than the end of the next month after the delivery is accepted.

.
In order to ensure the quality supply of medicines, it is clarified that the selected enterprises will independently select enterprises with strong distribution capabilities and good reputation to distribute the selected medicines.
In principle, each municipal co-ordination area shall have no less than 3, and the distribution scope shall cover all the co-ordination areas participating in the purchase with volume .
Medical institutions, and establish a production enterprise emergency reserve, inventory and capacity reporting system in accordance with the purchase and sale agreement
.
The time nodes of the purchase and sale agreement with volume are as follows: Before September 20, 2022, the selected enterprises should establish a distribution relationship covering the whole province
.
On September 30, 2022, the medical institution determined the purchase volume agreed in the agreement
.
Before October 20, 2022, in principle, the signing of the three-party purchase and sales agreement with volume will be completed.
If the agreement is seriously overdue due to the failure of timely maintenance of the distribution relationship or the failure of the company to respond in time, the purchase and sales agreement will be cancelled and the agreed purchase volume will be Deduct accordingly
.
In fact, since 2022, the centralized procurement of proprietary Chinese medicines has entered the fast lane
.
With the Centralized Procurement Alliance of Chinese Patent Medicines in 19 provinces including Hubei (17 groups, 76 medicines), the Centralized Procurement Alliance of Chinese Patent Medicines in 6 provinces including Guangdong (53 medicines), and the Special Collection of Chinese Patent Medicines in Shandong (15 groups, 67 medicines) successively The implementation has accumulated rich experience in the centralized procurement of proprietary Chinese medicines
.
In order to implement the requirement of "speeding up and expanding coverage" for centralized procurement with volume, the National Medical Insurance Bureau clearly requires that by the end of 2022, the number of drug varieties that all provinces (including inter-provincial alliances) in the country will carry out centralized procurement on their own will not be less than 100.
Contains proprietary Chinese medicines
.
Then, on July 21, the "Notice on the Filling and Reporting of Variety Demands for the Third Batch of Centralized Drug Purchases in Shandong Province (Special Procurement of Chinese Patent Medicines)" was released; The 2008 Beijing Municipal Notice on the Procurement of Chinese Patent Medicines with Volumes, unveils the prelude to the centralized procurement of Chinese patent medicines in Beijing
.
From the two alliances of Guangdong Alliance and Hubei Alliance to the current multi-point flowering, the varieties of Chinese patent medicines are also increasingly enriched.

.
With the continuous implementation of national support policies, my country's proprietary Chinese medicine research and development has entered a stage of rapid development! At present, Chinese patent medicine enterprises are relatively small and scattered, and the overall volume is still very large.
In the long run, the centralized procurement of Chinese patent medicines will benefit leading Chinese patent medicine enterprises with high-quality resources.
The quality assurance system supports the innovative development of Chinese patent medicines and promotes Chinese patent medicines to the world
.
  The time nodes of the purchase and sale agreement with the purchase and sale of pharmaceutical enterprises are as follows: Drugs